Clinicopathological factors associated with brain metastases development among breast cancer patients receiving neoadjuvant chemotherapy
Among patients treated with NAC for early-stage BC, residual nodal disease, inflammatory BC, and HER2+ or triple-negative subtype are associated with a higher risk of BrM development and whether BrM screening is warranted among patients with these high-risk features warrants evaluation.